Loading...
Market
Will the Russian mRNA cancer vaccine receive international regulatory approval by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Approval announcements from international health regulatory bodies
Story
Russia Develops Free mRNA Cancer Vaccine, Personalized for Patients, Launching in Early 2025 at 300,000 Rubles per Dose
Dec 18, 2024, 12:17 AM
Russia has announced the development of a personalized mRNA cancer vaccine, which will be distributed free of charge to patients starting in early 2025. The vaccine, designed to treat cancer rather than prevent it, will be tailored to individual patients based on their specific cancer types. Andrey Kaprin, the chief oncologist at the Ministry of Health, stated that while the vaccine's production cost is approximately 300,000 rubles per dose, it will be provided to patients at no cost. This initiative is part of Russia's broader efforts to enhance healthcare access and innovation in cancer treatment.
View original story
Similar markets
WHO Approval • 25%
EU Approval • 25%
US FDA Approval • 25%
No Major Approval • 25%
China • 25%
India • 25%
Brazil • 25%
Other • 25%
Positive • 25%
Neutral • 25%
Negative • 25%
Mixed • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%